ArticleJHLT open2025
ERAS including minimal Narcotic Pain Management Is Successful After Heart Transplant and LVAD Implantation: A Single Center Review.
Article in JHLT open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To assess the outcomes of an enhanced recovery after surgery (ERAS) protocol for heart failure patients receiving heart transplant or left ventricular assist device (LVAD) surgery. Methods: A single center, retrospective IRB study reviewed consecutive heart transplant and LVAD implantation patients from May 2020 to May 2022. Patients received an organized ERAS protocol. The following data points were evaluated: demographics, medication history, date of surgery, acute medication use, nutrition and bowel function assessment, time to liberate from mechanical ventilation, delirium screening, pain scores, functional status, time from implant to hospital discharge, and pain medications at both discharge and 30-day follow-up. Results: Thirty-two patients received ERAS: 18 heart transplants and 14 LVAD implants. One heart transplant was excluded from ERAS protocol due to delayed sternal closure for 72 hours after surgery. For a seven-day postoperative observation period, three patients (9%) had a positive delirium score. Pain scores were acceptable. The mean morphine milligram equivalent (MME) was 26.25 mg per day. No patient developed gastrointestinal complications. The average length of stay after surgery was 25 days for heart transplant, and 19 days for LVAD implant. No patients were prescribed opioids at discharge, and no patients reported opioid use over baseline at 30-days. Conclusion: For heart transplant and LVAD surgery, ERAS reduced opioid consumption, preserved mechanical ventilation time, and limited acute delirium. ERAS limited postoperative opioid induced gastroparesis while preserving acceptable pain scores, maintained the length of hospitalization, and prevented unnecessary opioid prescribing at discharge up to and including 30 days thereafter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.